Resources

J.P. Morgan’s healthcare conference may be wrapped up, but it has set some tangible momentum and without doubt a more buoyant mood for global life sciences going into 2026.

The UK’s biotech sector continues to break new ground, from sustainable medicine manufacturing to AI-driven healthcare advancements. This week, I analyse key developments shaping the industry, including the launch of the Sustainable Medicine Manufacturing Innovation Programme, the BIA’s role in the government’s Spending Review, and the UK’s leadership in cultivated meat.

Rinri Therapeutics, which is focused on transforming hearing loss treatment with regenerative cell therapy, announces that the novel surgical procedure to be used for regenerative cell delivery in its first-in-human trial has been published in the prestigious journal Nature Scientific Reports.

Read today's blog to learn about our latest reports, upcoming events and our CEO's thoughts on the upcoming budget.

This is part of a series of blogs focussing on hearing therapeutics from different sector perspectives. In this blog, Karen Steel shares her thoughts on what she perceives to be some of the biggest opportunities in relation to the development of new treatments for hearing loss.

In this blog, Albert Maguire-King, Media and Communications Executive at the BIA, recaps the recent Women in Biotech event in Manchester, where industry leaders discussed talent attraction, female leadership, and career advancement. The panel highlighted the importance of fostering home-grown talent, supporting female role models, and offering mentorship opportunities.

The political party conference season is in full swing, and the BIA is out in force in Liverpool for the Labour Party conference this week. I'm heartened to see the focus in ministerial speeches and the fringe on topics close to our hearts. Read on for updates on the Lib Dem conference, West Streeting speech and Invest in Women Taskforce.

This year, Rare Disease Day is being celebrated on 28 February, raising awareness and working towards equity in social opportunity, healthcare, and access to diagnosis and therapies for the 300 million people worldwide living with a rare disease. In this blog, Senior Policy and Public Affairs Executive at BIA, Joe Smale, explains the difference between equality and equity and reflects on the findings of recent BIA research, indicating public support for achieving equity of access to treatments for people living with rare diseases.